Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2166 January 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Tolvaptan		
Initial application — autosomal dominant polycystic kidney disease Applications only from a renal physician or any relevant practitioner on the recommendation of a renal physician. Approvals valid for 12 months.  Prerequisites(tick boxes where appropriate)  Patient has a confirmed diagnosis of autosomal dominant polycystic kidney disease  and Patient has an estimated glomerular filtration rate (eGFR) of greater than or equal to 25 ml/min/1.73 m² at treatment initiation  and Patient's disease is rapidly progressing, with a decline in eGFR of greater than or equal to 5 mL/min/1.73 m² within one-year or  Patient's disease is rapidly progressing, with an average decline in eGFR of greater than or equal to 2.5 mL/min/1.73 m² per year over a five-year period		
Renewal — autosomal dominant polycystic kidney disease  Current approval Number (if known):		
Patient has not developed end-stage renal disease, defined as an eGFR of less than 15 mL/min/1.73 m <sup>2</sup> and Patient has not undergone a kidney transplant		

I confirm the above details are correct and that in signing this form I understand I may be audited.